A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD. METHODS: We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach. RESULTS: An interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study. CONCLUSIONS: These data do not justify use of CoQ as a treatment to slow functional decline in HD. CLINICALTRIALSGOV IDENTIFIER: NCT00608881. CLASSIFICATION OF EVIDENCE: This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016 · cited 3×
“Patients were excluded due to (1) known sensitivity or intolerability to CoQ; (2) exposure to any investigational agent within 30 days of baseline; (3) unstable medical illness; (4) unstable psychiatric illness within 90 days of baseline; (5) substance abuse (DSMIV-R criteria) within 1 year of baseline; (6) pregnancy…”
BackgroundMethodResultSelf-citationBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405 · cited 1×
“Patients were excluded due to (1) known sensitivity or intolerability to CoQ; (2) exposure to any investigational agent within 30 days of baseline; (3) unstable medical illness; (4) unstable psychiatric illness within 90 days of baseline; (5) substance abuse (DSMIV-R criteria) within 1 year of baseline; (6) pregnancy…”
BackgroundTherapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Cited by
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Self-citationNeuroprotective Effect of Antioxidants in the Brain
Lee, K. H., Cha, M., & Lee, B. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197152 · Cited by 502
Coenzyme Q10 Supplementation in Aging and Disease
Hernández-Camacho, J. D., Bernier, M., López-Lluch, G., & Navas, P. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00044 · Cited by 366
Redox Signaling by Reactive Electrophiles and Oxidants
Parvez, S., Long, M. J. C., Poganik, J. R., & Aye, Y. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00698 · Cited by 359
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
Self-citation
Metadata
- Authors
- McGarry, A., McDermott, M., Kieburtz, K., de Blieck, E. A., Beal, F., Marder, K., Ross, C., Shoulson, I., Gilbert, P., Mallonee, W. M., Guttman, M., Wojcieszek, J., Kumar, R., LeDoux, M. S., Jenkins, M., Rosas, H. D., Nance, M., Biglan, K., Como, P., Dubinsky, R. M., Shannon, K. M., O'Suilleabhain, P., Chou, K., Walker, F., Martin, W., Wheelock, V. L., McCusker, E., Jankovic, J., Singer, C., Sanchez-Ramos, J., Scott, B., Suchowersky, O., Factor, S. A., Higgins, D. S., Molho, E., Revilla, F., Caviness, J. N., Friedman, J. H., Perlmutter, J. S., Feigin, A., Anderson, K., Rodriguez, R., McFarland, N. R., Margolis, R. L., Farbman, E. S., Raymond, L. A., Suski, V., Kostyk, S., Colcher, A., Seeberger, L., Epping, E., Esmail, S., Diaz, N., Fung, W. L. A., Diamond, A., Frank, S., Hanna, P., Hermanowicz, N., Dure, L. S., Cudkowicz, M., For the Huntington Study Group 2CARE Investigators and Coordinators, Huntington Study Group 2CARE Investigators and Coordinators, Adams, J., Jog, M., Hyson, C., Furtado, S., Duker, A., Armstrong, M., Lachner, C., Fernandez, H., Okun, M. S., Shprecher, D., Cartwright, M., Loy, C., Jiminez-Shahed, J., Robottom, B., Suter, G., Moore, T., Forsyth, J., Hurt, A., Belden, J., Price, K., Erickson, D., Nickels, B., Thompson, M. M., Cole, L., Megens, J., Makaji, E., Masse, S.-L., Malarick, K., Mook, L., Maya, S., Bender, A., Meyer, J., Turakhia, P., Harwood, K., Duderstadt, K., Lenarz, S., Hamerlinck, J., Edern, P., Hickey, C., Owens, A., Gibbons, C., Gray, C., Jaglin, J. A., Janko, K., Lawrence, H., Estes, B., Hayward, B., Johnson, A., Gode, A., Huet, G., Romero-Kersh, B., Wernette, K., Sullivan, E., Guyot, J., Konkle, J., O'Neill, C., King, P., Martin, A., Bautista, J., Mans, N., Griffith, J., Surles, E., Halton, S., Palao, A., Padron, N., Elliott, K., Oelke, L., Butterfield, L., Perry-Trice, P., Wyne, S., Pantella, C., Tainsh, L., Sperin, E., Evans, S., Gartner, M., Duffy, A., Kristof, P., Niles, L., Rainone, S., Wernle, A., Clouse, R., Cines, M., Dustin, K., Deeley, M., Merritt, S., Ferreri, H., McMurray, A., Sheinberg, A., Hughes-Gay, M., Ladonna, K., Chung, E., Lee, J., Goldstein, R., Esposito, L., Scoglio, N., Grana, M., Zimmerman, C., Blasucci, L. M., Thayer, W., Hawkins, J., Koch, J., Hunt, V., Bargoil, J., Scott, I., Tempkin, T., Stewart, L., Hayes, E., Galea, D., Belmar, B., Richardson, K., Hunter, C., Jimenez, E., Quesada, M., Levy, W., Blenke, A., Gauger, L., Stoner, J., Klimek, M. L., Sommerfeld, B., Eglow, M., Regan, K., Neefus, E., Malikowski, M., Radam, T., Zomok, M., Lannon, M., Agramonte, R., Hartlein, J., Nickerson, C., Gibson, S., Monari, E. H., Swartz, C., Smith-Bova, A., Jones, R., Wielinski, C., Graham, S., Gunn, D., & McMillan, J.
- Venue
- Neurology
- Published
- 2017-01-10
- Volume
- 88
- Issue
- 2
- Pages
- 152-159
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2557765283
- Cited by
- 139
- References
- 12
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000003478
- The paper
- McGarry, A., McDermott, M., Kieburtz, K., de Blieck, E. A., Beal, F., Marder, K., Ross, C., Shoulson, I., Gilbert, P., Mallonee, W. M., Guttman, M., Wojcieszek, J., Kumar, R., LeDoux, M. S., Jenkins, M., Rosas, H. D., Nance, M., Biglan, K., Como, P., . . . McMillan, J. (2017). A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. https://doi.org/10.1212/wnl.0000000000003478
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.